



## Published research demonstrates high specificity of Alzinova's ALZ-201 antibody which may contribute to good efficacy and favourable side-effect profile

Alzinova AB (publ) ("Alzinova" or the "Company") announces today that a new scientific article has been published in the prestigious journal *Alzheimer's Research & Therapy* presenting preclinical results demonstrating that the ALZ-201 antibody has specificity for the toxic oligomers believed to be the cause of Alzheimer's disease. Furthermore, the research shows that ALZ-201 has the potential to be "best-in-class" in the clinic with good efficacy and more favourable side-effect profile compared to other candidates.

The article presents new preclinical data on Alzinova's antibody ALZ-201 demonstrating its unique specificity for a very toxic form of the peptide amyloid- $\beta$ 1-42 (A $\beta$ 42). This toxic A $\beta$ 42 is in an oligomeric form, which are different from the A $\beta$ 42 that aggregates into the plaques in the brain of patients. Oligomers are considered to be the form of A $\beta$  that drives the disease. Given the antibody's unique binding profile, it has the potential to become clinical best-in-class with good efficacy and a favourable side-effect profile. The monoclonal antibody ALZ-201 was developed and validated using the clinical vaccine candidate ALZ-101.

The paper describes how a multidisciplinary approach was used to develop ALZ-201 as a new unique monoclonal antibody that specifically binds to artificial A $\beta$ 42 oligomers but not to other forms of the same peptide. This was also validated on human material, where ALZ-201 had a strong neutralizing effect on toxic A $\beta$  but did not bind to plaques. Taken together, the results indicate that it is a small amount of A $\beta$ 42 oligomers that account for the main toxic effect in AD, and that specificity for this form is likely to be necessary to obtain a good therapeutic effect of an antibody treatment.

The research presented in the paper also shows that ALZ-201 is completely different from other A $\beta$  monoclonal antibodies, including aducanumab, lecanemab, and gantenerumab, in that unlike these, it binds specifically to toxic oligomers.

Alzinova is currently developing a humanized version of ALZ-201 for phase 1 clinical trials in patients with Alzheimer's disease. The Company's research shows that both ALZ-201 and the ALZ-101 vaccine have best-in-class potential, and clinical results from other players in the field reinforce the Company's strategy.

### Chief Scientific Officer Anders Sandberg comments:

"We are very pleased to present our research results in the well-renowned scientific journal *Alzheimer's Research & Therapy*. The research described in the article clearly shows that a particular type of A $\beta$ 42 oligomer appears to be significantly more toxic than other forms of the



same peptide, and we present a unique monoclonal antibody that can specifically neutralize it. We also show that this specificity is lacking in other antibodies in clinical development. These results strongly warrant continued development of ALZ-201 as a potential drug for Alzheimer's disease.”

**For more information, please contact:**

Kristina Torfgård, CEO

Tel. +46 708 46 79 75

E-mail: [kristina.torfgard@alzinova.com](mailto:kristina.torfgard@alzinova.com)

*Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.*

**About Alzinova**

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A $\beta$ CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: [www.alzinova.com](http://www.alzinova.com)

**Attachments**

**Published research demonstrates high specificity of Alzinova's ALZ-201 antibody which may contribute to good efficacy and favourable side-effect profile**